Literature DB >> 12921148

Outcome of directly observed therapy for tuberculosis in Yokohama City, Japan.

K Tsuchida1, H Koyanagi.   

Abstract

BACKGROUND: Yokohama City is currently developing directly observed treatment (DOT) in its programme, and requires guidance on types of DOT appropriate for local conditions.
OBJECTIVE: To assess the effectiveness of DOT for tuberculosis treatment in a retrospective study under operational conditions in Yokohama City.
METHODS: We included 80 patients with sputum-positive tuberculosis, 39 enrolled in DOT and 41 self-administered patients. The study was done at the National Hospital for Chest Diseases and the Community Clinic, which provide tuberculosis services with a standard daily short-course regimen. The main outcome measures were cure and treatment completion.
RESULTS: The cure or treatment completion rate for the DOT and self-administered groups were respectively 87.2% and 68.3%. In a multivariate logistic regression model, cure or treatment completion was significantly associated with out-patient DOT (OR 4.04, 95%CI 1.22-13.33, P = 0.022).
CONCLUSION: DOT was shown to be significantly superior to the self-administered regimen. However, our results were from an impoverished population with city-sponsored apartments and supplementary benefits. Further research will be needed to know the effectiveness of DOT in the general population.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12921148

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  2 in total

Review 1.  ROLES OF PUBLIC HEALTH CENTERS (HOKENJO) IN TUBERCULOSIS CONTROL IN JAPAN.

Authors:  Nobuyuki Katsuda; Tomoya Hirosawa; Joshua A Reyer; Nobuyuki Hamajima
Journal:  Nagoya J Med Sci       Date:  2015-02       Impact factor: 1.131

2.  Adherence interventions and outcomes of tuberculosis treatment: A systematic review and meta-analysis of trials and observational studies.

Authors:  Narges Alipanah; Leah Jarlsberg; Cecily Miller; Nguyen Nhat Linh; Dennis Falzon; Ernesto Jaramillo; Payam Nahid
Journal:  PLoS Med       Date:  2018-07-03       Impact factor: 11.069

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.